Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.

Inclusion Criteria: * Female subject aged ≥18; * Subject presenting vaginal atrophy, dryness, dyspareunia or discomfort in the intimate area; * Subject who presents no other type of pathology of the area to be treated; * Subject who is willing to abstain from any cosmetic or surgical procedures in the treatment area during the clinical investigation; * Subject who is willing to participate in all study related activities and who is available for the duration of their participation in the investigation for follow-up; * Absence of a history of significant hypersensitivity to food and drugs or known sensitivity to hyaluronic acid; * Clinically and anamnestic healthy individual; * Arterial blood pressure (BP) (after 5 min. at rest in the supine position) systolic 90 - 140 mmHg and diastolic 50 - 90 mmHg; * Heart rate (HR) (after 5 min. at rest in the supine position) over 50 beats/min and less than 90 beats/min; * Respiratory rate between 12 - 24 breaths/min; * An axillar body temperature of up to 37 degrees celsius; * Clinical-laboratory examinations within the reference ranges or with no clinically significant abnormalities; * Negative AIDS/HIV test; * Negative pregnancy test for the women with reproductive potential; * A reliable and acceptable method of contraception for the women of child-bearing potential: * Signed written Informed Consent Form Exclusion Criteria: * Subject with known sensitivity to hyaluronic acid or significant hypersensitivity to food and drugs; * Subject with a history of vulvar cancer and/or previous regional radiotherapy; * Subject with genital prolapse with a surgical indication or stress incontinence with a surgical indication; * A subject who suffers from vaginism; * Subject with genital bleeding of unknown origin; * Subject with frequent or present active herpes simplex or herpes zoster local infection or active herpes simplex or herpes zoster infection in other sites; * Subject with a history of frequent or active local dermatitis (of the injection site), vulvar scaly papilloma, mycosis; bacterial infection or laboratory tests indicating for such; * A subject suffering from autoimmune diseases or who are undergoing treatment with immunosuppressors or immunotherapy; * Subject with uncontrolled systemic diseases or who are undergoing current treatment with antihypertensives, steroid anti-inflammatory drugs anticoagulants, aspirin, major antidepressants; * Pregnancy, postpartum period (6 months), lactation or post-lactation period (6 months); * Absence of a reliable and effective method of contraception for a subject with childbearing potential; * Subjects who are currently receiving another investigational treatment or who had participated in another clinical investigation within 30 days prior to study enrollment; * A subject who suffer from another medical condition or who are receiving medication that in the Principal Investigator's judgment would prohibit the inclusion in the study; * Subject with limited mental activity and consistent comprehension ability; sportsmen and individuals on strenuous physical loading; prisoners; * Refusal to sign the Informed Consent Form.